BioCryst Pharmaceuticals Inc. [BCRX] Is Currently -4.09 below its 200 Period Moving Avg: What Does This Mean?

BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] plunged by -$0.35 during the normal trading session on Thursday and reaching a high of $8.62 during the day while it closed the day at $8.21. The company report on March 8, 2023 that CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



BioCryst Pharmaceuticals Inc. stock has also loss -7.34% of its value over the past 7 days. However, BCRX stock has declined by -24.61% in the 3 months of the year. Over the past six months meanwhile, it has lost -40.64% and lost -28.48% year-on date.

The market cap for BCRX stock reached $1.56 billion, with 186.93 million shares outstanding and 184.56 million shares in the current float. Compared to the average trading volume of 2.98M shares, BCRX reached a trading volume of 3793177 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $15.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Needham have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 22, 2023. While these analysts kept the previous recommendation, Evercore ISI raised their target price from $14 to $16. The new note on the price target was released on November 02, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.44, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 5.76.

BCRX stock trade performance evaluation

BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.34. With this latest performance, BCRX shares dropped by -23.13% in over the last four-week period, additionally sinking by -40.64% over the last 6 months – not to mention a drop of -53.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 30.17, with the RSI for the last a single of trading hit 25.16, and the three-weeks RSI is set at 33.53 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 10.17, while it was recorded at 8.61 for the last single week of trading, and 11.70 for the last 200 days.

BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -54.81 and a Gross Margin at +97.03. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -91.24.

BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.90.

Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 44.80%.

BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions

There are presently around $1,291 million, or 81.10% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 14,918,955, which is approximately 8.305% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 14,204,395 shares of the stock with an approximate value of $116.62 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $104.36 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 130 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 21,925,229 shares. Additionally, 97 investors decreased positions by around 12,983,395 shares, while 43 investors held positions by with 122,377,385 shares. The mentioned changes placed institutional holdings at 157,286,009 shares, according to the latest SEC report filing. BCRX stock had 34 new institutional investments in for a total of 6,242,322 shares, while 35 institutional investors sold positions of 4,625,199 shares during the same period.


Please enter your comment!
Please enter your name here